Logo image of LMAT

LEMAITRE VASCULAR INC (LMAT) Stock Overview

USA - NASDAQ:LMAT - US5255582018 - Common Stock

89.21 USD
+0.2 (+0.22%)
Last: 10/24/2025, 8:00:00 PM
89.3 USD
+0.09 (+0.1%)
After Hours: 10/24/2025, 8:00:00 PM

LMAT Key Statistics, Chart & Performance

Key Statistics
Market Cap2.02B
Revenue(TTM)234.64M
Net Income(TTM)47.12M
Shares22.64M
Float20.87M
52 Week High109.58
52 Week Low71.42
Yearly Dividend0.64
Dividend Yield0.9%
EPS(TTM)2.06
PE43.31
Fwd PE35.2
Earnings (Next)11-06 2025-11-06/amc
IPO2006-10-19
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment


LMAT short term performance overview.The bars show the price performance of LMAT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 2 -2 4 6 8

LMAT long term performance overview.The bars show the price performance of LMAT in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80 100

The current stock price of LMAT is 89.21 USD. In the past month the price increased by 5.96%. In the past year, price increased by 4.17%.

LEMAITRE VASCULAR INC / LMAT Daily stock chart

LMAT Latest News, Press Relases and Analysis

2 months ago - By: Zacks Investment Research
3 months ago - By: Zacks Investment Research
3 months ago - By: The Motley Fool

LMAT Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 25.42 220.78B
ISRG INTUITIVE SURGICAL INC 63.47 195.91B
BSX BOSTON SCIENTIFIC CORP 34.27 149.82B
SYK STRYKER CORP 29.71 145.96B
MDT MEDTRONIC PLC 16.94 120.15B
BDX BECTON DICKINSON AND CO 13.02 53.26B
IDXX IDEXX LABORATORIES INC 53.36 51.27B
EW EDWARDS LIFESCIENCES CORP 29.61 44.68B
RMD RESMED INC 27.17 37.87B
GEHC GE HEALTHCARE TECHNOLOGY 16.77 35.68B
PHG KONINKLIJKE PHILIPS NVR- NY 17.26 27.76B
DXCM DEXCOM INC 41.37 27.58B

About LMAT

Company Profile

LMAT logo image LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company is headquartered in Burlington, Massachusetts and currently employs 651 full-time employees. The company went IPO on 2006-10-19. The firm develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which used in open vascular surgery and dialysis access. The company also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold primarily in the United States, Europe, Canada, and Asia Pacific.

Company Info

LEMAITRE VASCULAR INC

63 2nd Ave

Burlington MASSACHUSETTS 01803 US

CEO: George W. LeMaitre

Employees: 658

LMAT Company Website

LMAT Investor Relations

Phone: 17812212266

LEMAITRE VASCULAR INC / LMAT FAQ

What does LEMAITRE VASCULAR INC do?

LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company is headquartered in Burlington, Massachusetts and currently employs 651 full-time employees. The company went IPO on 2006-10-19. The firm develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which used in open vascular surgery and dialysis access. The company also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold primarily in the United States, Europe, Canada, and Asia Pacific.


Can you provide the latest stock price for LEMAITRE VASCULAR INC?

The current stock price of LMAT is 89.21 USD. The price increased by 0.22% in the last trading session.


Does LEMAITRE VASCULAR INC pay dividends?

LEMAITRE VASCULAR INC (LMAT) has a dividend yield of 0.9%. The yearly dividend amount is currently 0.64.


What is the ChartMill technical and fundamental rating of LMAT stock?

LMAT has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 7 out of 10.


Can you provide the upcoming dividend date for LEMAITRE VASCULAR INC?

The next ex-dividend date for LEMAITRE VASCULAR INC (LMAT) is August 21, 2025.


Is LEMAITRE VASCULAR INC (LMAT) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LMAT.


What is the market capitalization of LMAT stock?

LEMAITRE VASCULAR INC (LMAT) has a market capitalization of 2.02B USD. This makes LMAT a Mid Cap stock.


LMAT Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to LMAT. When comparing the yearly performance of all stocks, LMAT turns out to be only a medium performer in the overall market: it outperformed 56.81% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

LMAT Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to LMAT. Both the health and profitability get an excellent rating, making LMAT a very profitable company, without any liquidiy or solvency issues.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LMAT Financial Highlights

Over the last trailing twelve months LMAT reported a non-GAAP Earnings per Share(EPS) of 2.06. The EPS increased by 23.35% compared to the year before.


Industry RankSector Rank
PM (TTM) 20.08%
ROA 8.16%
ROE 12.99%
Debt/Equity 0.46
Chartmill High Growth Momentum
EPS Q2Q%15.38%
Sales Q2Q%15.01%
EPS 1Y (TTM)23.35%
Revenue 1Y (TTM)14.11%

LMAT Forecast & Estimates

17 analysts have analysed LMAT and the average price target is 106.87 USD. This implies a price increase of 19.8% is expected in the next year compared to the current price of 89.21.

For the next year, analysts expect an EPS growth of 19.93% and a revenue growth 13.86% for LMAT


Analysts
Analysts78.82
Price Target106.87 (19.8%)
EPS Next Y19.93%
Revenue Next Year13.86%

LMAT Ownership

Ownership
Inst Owners95.25%
Ins Owners7.8%
Short Float %5.91%
Short Ratio7.56